Showing results (41-50 of 82) with videos related to
Sort By:
Pageof 9
Neurology and Therapy|June 11, 2025
Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST TrialRajesh Pahwa, Eric Molho, Mark Lew, et al.Journal of Parkinson'S Disease|January 14, 2020
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's DiseaseCaroline M Tanner, Rajesh Pahwa, Robert A Hauser, et al.Neurology. Clinical Practice|June 5, 2023
Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HTStuart H Isaacson, Mark Goldstein, Rajesh Pahwa, et al.Movement Disorders Clinical Practice|May 22, 2018
Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102Stuart H Isaacson, Stanley Fahn, Rajesh Pahwa, et al.Journal of Neurology|March 28, 2024
Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label studyJan Kassubek, Stewart A Factor, Ernest Balaguer, et al.Clinical Parkinsonism & Related Disorders|August 23, 2024
Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson's disease experiencing OFF episodes: A modified Delphi panelStuart H Isaacson, Richard Dewey, Robert A Hauser, et al.Expert Review of Neurotherapeutics|November 5, 2016
Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspectiveStuart H Isaacson, Stanley Fisher, Fiona Gupta, et al.The Journal of Clinical Psychiatry|November 30, 2022
Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive DyskinesiaRichard Jackson, Matthew N Brams, Noelle E Carlozzi, et al.JAMA Neurology|January 14, 2020
Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical TrialStuart H Isaacson, William Ondo, Carlayne E Jackson, et al.Parkinsonism & Related Disorders|April 18, 2019
Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's diseaseRobert A Hauser, Stuart H Isaacson, Aaron Ellenbogen, et al.Pageof 9